Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sally Beauty hire

This article was originally published in The Rose Sheet

Executive Summary

Borders Inc. exec Michael Spinozzi appointed president of Sally Beauty Supply for the U.S. and Canada, charged with directing "store operations, merchandising/purchasing, advertising, customer service, customer relationship marketing" and other responsibilities, Alberto-Culver company announces June 5. Exec also will be responsible for directing the overall strategic direction for more than 2,100 Sally Beauty stores in the U.S. and Canada, firm notes. Spinozzi will report to Gary Winterhalter, president of Sally Beauty and Beauty Systems Group. Exec most recently served as exec VP, Chief Product Officer for Borders. Alberto will decide by its July board meeting whether to split Sally Beauty and Beauty Systems Group divisions from the firm's consumer products unit (1"The Rose Sheet" May 8, 2006, p. 6)...

You may also be interested in...



Alberto-Culver Weighs Options For Beauty Supply Division

Alberto-Culver will decide by its July board meeting whether to split the Sally Beauty and Beauty Systems Group divisions from the consumer products unit, President and CEO Howard Bernick stated during an April 27 analyst meeting

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel